For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Keyword

Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC a...

Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China

Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC at ASCO 2021 ( Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China )

ASCO 2021: Precision and molecular reporting for prostate cancer

Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA

ASCO 2021: Precision and molecular reporting for prostate cancer ( Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA )

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethaso...

Prof Thierry Facon - Chu De Lille, Lille, France

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible...

Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA

PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL

Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlan...

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL ( Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands )

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to pr...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PROMISE-GIM6: GnRH agonist use during chemotherapy for early breast cancer to preserve ovarian function ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial ...

Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma ( Prof Brian Van Tine - Washington University in St. Louis, St. Louis, USA )

Adjuvant chemo following chemoradiation as treatment for locally advanced cervic...

Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia

Adjuvant chemo following chemoradiation as treatment for locally advanced cervical cancer compared to chemoradiation alone ( Dr Linda Mileshkin - Peter MacCallum Cancer Center, Melbourne, Australia )

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma ( Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA )

Highlights from ASCO 2021

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Highlights from ASCO 2021 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resect...

Dr Jonathan Spicer - McGill University, Montreal, Canada

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC ( Dr Jonathan Spicer - McGill University, Montreal, Canada )

More from ecancer